{"id":132319,"date":"2022-08-03T14:20:23","date_gmt":"2022-08-03T18:20:23","guid":{"rendered":"https:\/\/44.250.171.167\/?p=132319"},"modified":"2023-05-02T09:53:01","modified_gmt":"2023-05-02T13:53:01","slug":"earnings-infographic-dr-lal-pathlabs-q1-2023-revenue-and-profit-decline","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/earnings-infographic-dr-lal-pathlabs-q1-2023-revenue-and-profit-decline\/","title":{"rendered":"Earnings Infographic: Dr. Lal PathLabs Q1 2023 revenue and profit decline"},"content":{"rendered":"\n<p>Dr. Lal PathLabs Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/lalpathlab\/\">NSE: LALPATHLAB<\/a>), a leading provider of diagnostic and related healthcare services, has reported lower revenues and earnings for the first quarter of 2023. The company also announced an interim dividend of \u20b96 per share. <\/p>\n\n\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-132320 size-full\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg\" alt=\"\" width=\"1280\" height=\"1685\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg 1280w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic-228x300.jpg 228w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic-778x1024.jpg 778w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic-768x1011.jpg 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic-1167x1536.jpg 1167w\" sizes=\"auto, (max-width: 1280px) 100vw, 1280px\" \/><\/p>\n\n\n<p>First-quarter revenues dropped 17% year-over-year to \u20b9502.7 crores, hurt by a sharp decline in COVID &amp; Allied revenues. Meanwhile, non-COVID revenue increased 25% to \u20b9481.8 crores.<\/p>\n\n\n\n<p>Reflecting the weak top-line performance, the company&#8217;s total comprehensive income declined to \u20b957.7 crores from \u20b9133.6 crores in the prior-year quarter. On a per-share basis, earnings were \u20b96.96, down 56%.<\/p>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<p class=\"has-text-align-center\"><strong><a href=\"https:\/\/44.250.171.167\/earnings-call-transcripts\/\">Read management\/analysts&#8217; comments on quarterly reports<\/a><\/strong><\/p>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<p>&#8220;The industry has more than adequate headroom to grow in FY23, where with an effective vaccination drive and improved patient care infrastructure, India has successfully met the challenges posed during the pandemic. Dr. Lal PathLabs is committed to control the epidemic of non-communicable diseases or lifestyle diseases that are responsible for nearly 65% deaths in India,&#8221; said Dr. Arvind Lal, executive chairman of the company. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Lal PathLabs Ltd (NSE: LALPATHLAB), a leading provider of diagnostic and related healthcare services, has reported lower revenues and earnings for the first quarter of 2023. The company also announced an interim dividend of \u20b96 per share. First-quarter revenues dropped 17% year-over-year to \u20b9502.7 crores, hurt by a sharp decline in COVID &amp; Allied [&hellip;]<\/p>\n","protected":false},"author":1882,"featured_media":132320,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"#Earnings #Infographic: Dr. Lal #PathLabs Q1 2023 revenue and profit decline","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392,6349,5747],"tags":[8665,1115],"class_list":["post-132319","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","category-transcripts","category-healthcare-stocks","tag-diagnostics","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":169027,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q4fy25-81-rise-in-profits\/","url_meta":{"origin":132319,"position":0},"title":"Dr Lal Pathlabs Ltd Q4FY25; 81% rise in Profits","author":"Divyansh_Kasana","date":"July 7, 2025","format":false,"excerpt":"Dr. Lal PathLabs Limited is one of India\u2019s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":165284,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q2fy25-18-rise-in-profits\/","url_meta":{"origin":132319,"position":1},"title":"Dr Lal Pathlabs Ltd Q2FY25; 18% rise in Profits","author":"Divyansh_Kasana","date":"October 29, 2024","format":false,"excerpt":"Dr. Lal PathLabs Limited is one of India\u2019s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/pa.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/pa.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/pa.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/pa.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/pa.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/pa.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":167589,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q3fy25-20-rise-in-profits\/","url_meta":{"origin":132319,"position":2},"title":"Dr Lal Pathlabs Ltd Q3FY25; 20% rise in Profits","author":"Divyansh_Kasana","date":"March 26, 2025","format":false,"excerpt":"Dr. Lal PathLabs Limited is one of India\u2019s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/LAL.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/LAL.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/LAL.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/LAL.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/LAL.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/LAL.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":139887,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-limited-q3-fy23-net-profit-down-by-8\/","url_meta":{"origin":132319,"position":3},"title":"Dr. Lal PathLabs Limited Q3 FY23; Net Profit  Down By 8%","author":"Hardik Bhandare","date":"February 2, 2023","format":false,"excerpt":"Dr. Lal PathLabs Limited (NSE: LALPATHLAB) reported a Revenue from Operations of \u20b9489.4 Crores, a decline of 1.5% from the previous year. The Consolidated Net Profit for the business also decreased by 8% year over year, to \u20b953.6 Crore from \u20b958.2 Crore. Earnings per Share is \u20b96.35 for this quarter.","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":150148,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q1fy24-45-rise-in-profits\/","url_meta":{"origin":132319,"position":4},"title":"Dr Lal Pathlabs Ltd Q1FY24; 45% rise in Profits.","author":"Divyansh_Kasana","date":"July 27, 2023","format":false,"excerpt":"Dr. Lal PathLabs Limited is one of India\u2019s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-291.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-291.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-291.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-291.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-291.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-291.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":163744,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q1fy25-29-rise-in-profits\/","url_meta":{"origin":132319,"position":5},"title":"Dr Lal Pathlabs Ltd Q1FY25; 29% rise in Profits","author":"Chirag Gupta","date":"August 9, 2024","format":false,"excerpt":"Dr. Lal PathLabs Limited is one of India\u2019s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-66.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-66.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-66.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-66.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-66.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-66.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/132319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1882"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=132319"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/132319\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/132320"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=132319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=132319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=132319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}